Companies Organon & Co.
Organon (OGN): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Organon & Co.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $3,737,009FY2023
- $4,129,939FY2024
- $5,772,848FY2025
CEO total pay was $5,772,848 in fiscal 2025, up from $4,129,939 in fiscal 2024.
FY2025: salary $819,231 · bonus $0 · stock awards $3,365,818 · option awards $749,998
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kevin Ali | $1,088,462 | $0 | $10,251,989 | $3,249,999 | $0 | $0 | $1,222,846 | $15,813,296 |
| Former Chief Executive Officer | ||||||||
| Joseph Morrissey | 819,231 | 0 | 3,365,818 | 749,998 | 602,433 | 0 | 235,368 | 5,772,848 |
| Interim Chief Executive Officer | ||||||||
| Matthew Walsh | 919,231 | 0 | 3,036,171 | 962,498 | 532,800 | 0 | 235,504 | 5,686,204 |
| EVP and Chief Financial Officer | ||||||||
| Juan Camilo Arjona Ferreira | 734,615 | 0 | 1,892,658 | 599,998 | 437,760 | 0 | 157,456 | 3,822,487 |
| EVP and Head of R&D and Chief Medical Officer | ||||||||
| Rachel Stahler | 706,923 | 0 | 1,734,932 | 550,000 | 411,840 | 0 | 147,924 | 3,551,619 |
| EVP and Chief Digital & Growth Officer | ||||||||
| Kirke Weaver | 676,923 | 0 | 1,734,932 | 550,000 | 394,560 | 0 | 186,560 | 3,542,975 |
| EVP, General Counsel and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Kevin Ali | $15,813,296 | $17,117,424 | $14,832,272 | ↓ −1,304,128 |
| Joseph Morrissey | 5,772,848 | 4,129,939 | 3,737,009 | ↑ +1,642,909 |
| Matthew Walsh | 5,686,204 | 5,746,922 | 5,212,866 | ↓ −60,718 |
| Juan Camilo Arjona Ferreira | 3,822,487 | 3,599,751 | — | ↑ +222,736 |
| Rachel Stahler | 3,551,619 | — | — | — |
| Kirke Weaver | 3,542,975 | — | 3,192,693 | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Organon's executive compensation program is designed with our governance principles and compensation philosophy in mind. We believe in providing a market-competitive target compensation opportunity for our executives, delivered through a mix of base salary, short-term and long-term incentives.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Korn Ferry |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Matthew Walsh | PSU | 2025-03-31 | 64,640 | 129,281 | — | 258,562 | $2,073,682 |
| Kirke Weaver | RSU | 2025-03-31 | — | — | 36,937 | — | 549,992 |
| Juan Camilo Arjona Ferreira | RSU | 2025-03-31 | — | — | 40,295 | — | 599,993 |
| Kirke Weaver | PSU | 2025-03-31 | 36,937 | 73,875 | — | 147,750 | 1,184,940 |
| Kevin Ali | RSU | 2025-03-31 | — | — | 218,267 | — | 3,249,995 |
| Matthew Walsh | OPTION | 2025-03-31 | — | — | 317,656 | — | 962,498 |
| Joseph Morrissey | OPTION | 2025-03-31 | — | — | 247,524 | — | 749,998 |
| Rachel Stahler | RSU | 2025-03-31 | — | — | 36,937 | — | 549,992 |
| Joseph Morrissey | RSU | 2025-03-31 | — | — | 50,369 | — | 749,994 |
| Joseph Morrissey | PSU | 2025-03-31 | 50,369 | 100,738 | — | 201,476 | 1,615,828 |
| Juan Camilo Arjona Ferreira | OPTION | 2025-03-31 | — | — | 198,019 | — | 599,998 |
| Kevin Ali | OPTION | 2025-03-31 | — | — | 1,072,607 | — | 3,249,999 |
| Kevin Ali | PSU | 2025-03-31 | 218,267 | 436,534 | — | 873,068 | 7,001,994 |
| Joseph Morrissey | RSU | 2025-11-13 | — | — | 131,233 | — | 999,995 |
| Rachel Stahler | OPTION | 2025-03-31 | — | — | 181,518 | — | 550,000 |
| Kirke Weaver | OPTION | 2025-03-31 | — | — | 181,518 | — | 550,000 |
| Rachel Stahler | PSU | 2025-03-31 | 36,937 | 73,875 | — | 147,750 | 1,184,940 |
| Matthew Walsh | RSU | 2025-03-31 | — | — | 64,640 | — | 962,490 |
| Juan Camilo Arjona Ferreira | PSU | 2025-03-31 | 40,295 | 80,591 | — | 161,182 | 1,292,665 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Matthew Walsh | $962,490 | $2,073,682 | $962,498 | 51.9% |
| Kirke Weaver | 549,992 | 1,184,940 | 550,000 | 51.9% |
| Juan Camilo Arjona Ferreira | 599,993 | 1,292,665 | 599,998 | 51.9% |
| Kevin Ali | 3,249,995 | 7,001,994 | 3,249,999 | 51.9% |
| Joseph Morrissey | 1,749,989 | 1,615,828 | 749,998 | 39.3% |
| Rachel Stahler | 549,992 | 1,184,940 | 550,000 | 51.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kirke Weaver | RSU | 6,201 | — | $44,461 |
| Juan Camilo Arjona Ferreira | RSU | 6,447 | — | 46,225 |
| Rachel Stahler | RSU | 6,555 | — | 46,999 |
| Joseph Morrissey | RSU | 7,795 | — | 55,890 |
| Matthew Walsh | RSU | 12,047 | — | 86,377 |
| Kevin Ali | RSU | 14,055 | — | 190,024 |
| Kirke Weaver | RSU | 15,514 | — | 111,235 |
| Rachel Stahler | RSU | 16,401 | — | 117,595 |
| Juan Camilo Arjona Ferreira | RSU | 17,730 | — | 127,124 |
| Joseph Morrissey | RSU | 19,504 | — | 139,844 |
| Kirke Weaver | Option | 22,265 | 23.52 | — |
| Rachel Stahler | Option | 23,537 | 23.52 | — |
| Joseph Morrissey | Option | 27,990 | 23.52 | — |
| Matthew Walsh | RSU | 30,142 | — | 216,118 |
| Rachel Stahler | RSU | 36,937 | — | 264,838 |
| Kirke Weaver | RSU | 36,937 | — | 264,838 |
| Juan Camilo Arjona Ferreira | RSU | 40,295 | — | 288,915 |
| Matthew Walsh | Option | 43,257 | 23.52 | — |
| Kirke Weaver | PSU | 46,542 | — | 333,706 |
| Rachel Stahler | PSU | 49,202 | — | 352,778 |
| Joseph Morrissey | RSU | 50,369 | — | 361,146 |
| Juan Camilo Arjona Ferreira | PSU | 53,191 | — | 381,379 |
| Joseph Morrissey | PSU | 58,510 | — | 419,517 |
| Kirke Weaver | Option | 63,544 | 18.8 | — |
| Matthew Walsh | RSU | 64,640 | — | 463,469 |
| Rachel Stahler | Option | 67,175 | 18.8 | — |
| Juan Camilo Arjona Ferreira | Option | 72,622 | 18.8 | — |
| Rachel Stahler | PSU | 73,875 | — | 529,684 |
| Kirke Weaver | PSU | 73,875 | — | 529,684 |
| Joseph Morrissey | Option | 79,884 | 18.8 | — |
| Juan Camilo Arjona Ferreira | PSU | 80,591 | — | 577,837 |
| Matthew Walsh | PSU | 90,425 | — | 648,347 |
| Joseph Morrissey | PSU | 100,738 | — | 722,291 |
| Matthew Walsh | Option | 123,457 | 18.8 | — |
| Matthew Walsh | PSU | 129,281 | — | 926,945 |
| Joseph Morrissey | RSU | 131,233 | — | 940,941 |
| Rachel Stahler | Option | 181,518 | 14.89 | — |
| Kirke Weaver | Option | 181,518 | 14.89 | — |
| Juan Camilo Arjona Ferreira | Option | 198,019 | 14.89 | — |
| Joseph Morrissey | Option | 247,524 | 14.89 | — |
| Matthew Walsh | Option | 317,656 | 14.89 | — |
| Kevin Ali | RSU | 3,048,763 | — | 41,219,276 |
| Kevin Ali | RSU | 3,337,437 | — | 45,122,148 |
| Kevin Ali | RSU | 3,860,018 | — | 34,546,643 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Carrie S. CoxEmployee director · Board Chair | $220,645 | $240,000 | $0 | — | $0 | $460,645 |
| Shalini SharpIndependent · Audit (Chair) | 145,000 | 240,000 | 0 | 0 | 0 | 385,000 |
| Robert EssnerIndependent · Lead Independent Director · ESG (Chair) · Portfolio Development Committee | 144,140 | 240,000 | 0 | 0 | 0 | 384,140 |
| Philip OzuahIndependent · Talent · ESG | 140,000 | 240,000 | 0 | 0 | 0 | 380,000 |
| Deborah LeoneIndependent · Audit · Portfolio Development Committee | 130,000 | 240,000 | 0 | 0 | 0 | 370,000 |
| R. Alan EzekowitzIndependent · Talent · ESG | 130,000 | 240,000 | 0 | 0 | 0 | 370,000 |
| Cynthia M. PattonIndependent · Audit · Talent | 130,000 | 240,000 | 0 | 0 | 0 | 370,000 |
| Helene GayleIndependent · Audit · ESG | 123,656 | 240,000 | 0 | 0 | 0 | 363,656 |
| Grace PumaIndependent · Talent (Chair) · Portfolio Development Committee · Not standing for re-election | 120,000 | 240,000 | 0 | 0 | 0 | 360,000 |
| Ramona SequeiraIndependent · Portfolio Development Committee · Newly elected | 60,000 | 220,000 | 0 | 0 | 0 | 280,000 |
| Rochelle B. LazarusIndependent · Talent · Portfolio Development Committee | — | — | 0 | 0 | 0 | — |
Board fee structure and ownership guideline
| Annual cash retainer | $120,000 |
|---|---|
| Annual equity retainer | $240,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 270,000 |
| Stock ownership guideline | $600,000 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,343,441 |
| Equity awards (grant-date value) | $2,380,000 |
| All other compensation | $0 |
| Total cost of the board | $3,723,441 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Organon as a peer
Companies that benchmark against OGN
6 companies name OGN as a compensation peer
The list of companies that name OGN as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies Organon & Co. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Incyte Corporation | 2025 | William Meury | $647,260 | $27,509,657 | $2,573,998 | $1,300,000 | $32,085,952 |
| 2 | Baxter International Inc. | 2025 | Andrew Hider | 499,315 | 23,133,518 | 3,185,053 | 820,125 | 29,805,182 |
| 3 | Iqvia Holdings Inc. | 2025 | Ari Bousbib | 1,800,000 | 15,749,957 | 4,528,317 | 4,966,127 | 28,128,245 |
| 4 | Biogen Inc. | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 5 | Boston Scientific Corporation | 2025 | Michael Mahoney | 1,442,603 | 13,608,056 | 3,749,980 | 4,002,001 | 23,532,050 |
| 6 | Vertex Pharmaceuticals Incorporated | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 7 | Intuitive Surgical, Inc. | 2025 | David Rosa | 858,750 | 18,674,872 | 0 | 1,373,859 | 20,997,480 |
| 8 | Jazz Pharmaceutical Plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 9 | Zoetis Inc. | 2025 | Kristin Peck | 1,350,000 | 10,218,583 | 3,406,229 | 2,187,000 | 19,046,509 |
| 10 | Edwards Lifesciences Corporation | 2025 | Bernard Zovighian | 1,192,500 | 7,167,024 | 6,499,109 | 2,406,537 | 17,454,255 |
| 11 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 12 | Viatris Inc. | 2025 | Scott Smith | 1,448,654 | 10,150,013 | 0 | 2,973,660 | 15,273,331 |
| 13 | Elanco Animal Health Incorporated | 2025 | Jeffrey Simmons | 1,200,000 | 9,000,000 | 3,000,004 | 1,700,400 | 14,925,756 |
| 14 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 15 | Regeneron Pharmaceuticals, Inc. | 2025 | Leonard Schleifer | 1,979,922 | — | — | 3,682,655 | 7,280,549 |
| 16 | Catalent, Inc. | 2023 | Alessandro Maselli | 925,000 | 3,850,216 | 1,650,019 | 0 | 6,583,672 |
| 17 | Avantor, Inc. | 2025 | Emmanuel Ligner | 379,297 | 2,499,990 | 2,499,998 | 330,038 | 5,895,624 |
| 18 | Organon & Co. | 2025 | Joseph Morrissey | 819,231 | 3,365,818 | 749,998 | 602,433 | 5,772,848 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Organon & Co. | 72% | PSU 50 · RSU 25 · Options 25 | Yes — Three-Year Relative TSR | Korn Ferry |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Option 20 · RSU 20 | No | Semler Brossy |
| Avantor, Inc. | not disclosed | PSU 50 · Options 25 · RSU 25 | Yes — TSR Relative to Comparator Group | FW Cook |
| Baxter International Inc. | not disclosed | PSU 50 · RSU 25 · Option 25 | No | Aon |
| Biogen Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| Boston Scientific Corporation | 173% | PSU 50 · RSU 25 · Options 25 | No | Semler Brossy Consulting Group, LLC |
| Catalent, Inc. | 0% | PSU 50 · Option 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Edwards Lifesciences Corporation | 127% | Options 50 · PSU 25 · RSU 25 | No | Semler Brossy Consulting Group |
| Elanco Animal Health Incorporated | not disclosed | not disclosed | No | Willis Towers Watson |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Incyte Corporation | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Intuitive Surgical, Inc. | 115.2% | RSU 50 · PSU 50 | No | Aon |
| Iqvia Holdings Inc. | not disclosed | PSU 75 · Options 25 | Yes | Meridian Compensation Partners, LLC |
| Jazz Pharmaceutical Plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Regeneron Pharmaceuticals, Inc. | 155% | Options 60 · RSU 40 | not disclosed | Pay Governance LLC |
| Vertex Pharmaceuticals Incorporated | not disclosed | PSU 55 · RSU 45 | No | Pearl Meyer |
| Viatris Inc. | 136.72% | PSU 65 · RSU 35 | No | Meridian Compensation Partners, LLC |
| Zoetis Inc. | 108% | PSU 50 · Options 25 · RSU 25 | Yes — Relative TSR | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 142,593,022 | 7,311,933 | 1,968,636 | 95.12% | Passed |
| 2025 | 2025-06-10 | 131,520,446 | 35,124,179 | 1,359,547 | 78.92% | Passed |
| 2024 | 2024-06-04 | 149,712,445 | 28,201,528 | 997,007 | 84.15% | Passed |
| 2023 | 2023-06-06 | 170,522,652 | 11,916,370 | 815,895 | 93.47% | Passed |
| 2022 | 2022-06-07 | 168,300,410 | 12,211,442 | 815,271 | 93.24% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | 95.12%a |
| 2025 | 2025-06-10 | 78.92%b |
| 2024 | 2024-06-04 | 84.15%c |
a. Approved under the standard stated in the filing — “Please cast your vote right away on all of the following proposals to ensure that your shares are represented: More Information Board's Recommendation Votes Required for Approval Effect of Abstentions Effect of Broker Non-Votes (if any) Proposal 1 Election of Directors Named Herein Page 32 FOR each Nominee Majority of votes cast Do not count (no effect) Do not count (no effect) Proposal 2 Approval, on a Non-Binding Advisory Basis, of the Compensation of Organon's Named Executive Officers Page 45 FOR Majority of the shares present and entitled to vote Count as vote "against" Do not count (no effect) Proposal 3 Approval of an Amendment and Restatement of the Organon & Co.”.
b. Approved under the standard stated in the filing — “Please cast your vote right away on all of the following proposals to ensure that your shares are represented: More Information Board's Recommendation Votes Required for Approval Effect of Abstentions Effect of Broker Non-Votes (if any) Proposal 1 Election of Directors Named Herein Page 33 FOR each Nominee Majority of votes cast Do not count (no effect) Do not count (no effect) Proposal 2 Approval, on a Non-Binding Advisory Basis, of the Compensation of Organon's Named Executive Officers Page 47 FOR Majority of the shares present and entitled to vote Count as vote "against" Do not count (no effect) Proposal 3 Approval of an Amendment and Restatement of the Organon & Co.”.
c. Approved under the standard stated in the filing — “Please cast your vote right away on all of the following proposals to ensure that your shares are represented: More Information Board's Recommendation Votes Required for Approval Effect of Abstentions Effect of Broker Non-Votes (if any) Proposal 1 Election of Class III Directors Named Herein Page 30 FOR each Nominee Majority of votes cast Do not count (no effect) Do not count (no effect) Proposal 2 Approval, on a Non-Binding Advisory Basis, of the Compensation of Organon's Named Executive Officers Page 45 FOR Majority of the shares present and entitled to vote Count as vote "against" Do not count (no effect) Proposal 3 Ratification of the Appointment of PricewaterhouseCoopers LLP as Organon's Independent Registered Public Accounting Firm for 2024 Page 85 FOR Majority of the shares present and entitled to vote Count as vote "against" Not expected (no effect) Why did I receive this proxy statement? The Board is soliciting your proxy to vote at the Annual Meeting because you were a shareholder of Organon at the close of business on April 8, 2024, the record date, and are entitled to vote at the Annual Meeting.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 79 : 1 |
|---|---|
| CEO total compensation | $6,097,395 |
| Median employee compensation | $77,368 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Lynette Holzbaur | SVP and Corporate Controller | 2026-05-06 | A | 26,448.37 | $13 | $353,080 | Common | Form 4 ↗ |
| Lynette Holzbaur | SVP and Corporate Controller | 2026-05-06 | D | 26,448.37 | 13 | 353,080 | Common | Form 4 ↗ |
| Lynette Holzbaur | SVP and Corporate Controller | 2026-05-06 | A | 45.94 | 0 | 0 | Common | Form 4 ↗ |
| Philip Ozuah | Director | 2026-06-12 | A | 17,857.14 | 13 | 240,000 | Derivative, Class A Common | Form 4 ↗ |
| Ramona Sequeira | Director | 2026-06-12 | A | 17,857.14 | 13 | 240,000 | Derivative, Class A Common | Form 4 ↗ |
| Robert Essner | Director | 2026-06-12 | A | 17,857.14 | 13 | 240,000 | Derivative, Class A Common | Form 4 ↗ |
| R. Alan Ezekowitz | Director | 2026-06-12 | A | 17,857.14 | 13 | 240,000 | Derivative, Class A Common | Form 4 ↗ |
| Helene Gayle | Director | 2026-06-12 | A | 17,857.14 | 13 | 240,000 | Derivative, Class A Common | Form 4 ↗ |
| Deborah Leone | Director | 2026-06-12 | A | 17,857.14 | 13 | 240,000 | Derivative, Class A Common | Form 4 ↗ |
| Cynthia M. Patton | Director | 2026-06-12 | A | 17,857.14 | 13 | 240,000 | Derivative, Class A Common | Form 4 ↗ |
| Shalini Sharp | Director | 2026-06-12 | A | 17,857.14 | 13 | 240,000 | Derivative, Class A Common | Form 4 ↗ |
| Rochelle B. Lazarus | Director | 2026-06-12 | A | 17,857.14 | 13 | 240,000 | Derivative, Class A Common | Form 4 ↗ |
| Juliana Papa Drinane | Head of Mfg & Supply | 2026-08-05 | D | 14,761 | 14 | 200,307 | Common | Form 4 ↗ |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO | 2026-08-11 | A | 11,519 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO | 2026-08-11 | A | 11,519 | 0 | 0 | Common | Form 4 ↗ |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO | 2026-08-11 | D | 4,134 | 14 | 56,305 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (79 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Kevin Ali. DEF 14A, filed 2026-04-24. Section “2025 Summary Compen sation Table” · page 73. As printed: 15,813,296. View filing ↗
- Section 01, Joseph Morrissey. DEF 14A, filed 2026-04-24. Section “2025 Summary Compen sation Table”. As printed: 5,772,848. View filing ↗
- Section 01, Matthew Walsh. DEF 14A, filed 2026-04-24. Section “2025 Summary Compen sation Table”. As printed: 5,686,204. View filing ↗
- Section 01, Juan Camilo Arjona Ferreira. DEF 14A, filed 2026-04-24. Section “2025 Summary Compen sation Table”. As printed: 3,822,487. View filing ↗
- Section 01, Rachel Stahler. DEF 14A, filed 2026-04-24. Section “2025 Summary Compen sation Table”. As printed: 3,551,619. View filing ↗
- Section 01, Kirke Weaver. DEF 14A, filed 2026-04-24. Section “2025 Summary Compen sation Table”. As printed: 3,542,975. View filing ↗
- Section 03, Matthew Walsh PSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Kirke Weaver RSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Juan Camilo Arjona Ferreira RSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Kirke Weaver PSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Ali RSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Walsh OPTION. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Joseph Morrissey OPTION. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Rachel Stahler RSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Joseph Morrissey RSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Joseph Morrissey PSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Juan Camilo Arjona Ferreira OPTION. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Ali OPTION. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Ali PSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Joseph Morrissey RSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Rachel Stahler OPTION. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Kirke Weaver OPTION. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Rachel Stahler PSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Walsh RSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Juan Camilo Arjona Ferreira PSU. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-24. Section “CEO Pay Ratio”. As printed: 79 : 1. View filing ↗
- Section 08, Carrie S. Cox. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 460,645. View filing ↗
- Section 08, Shalini Sharp. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 385,000. View filing ↗
- Section 08, Robert Essner. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 384,140. View filing ↗
- Section 08, Philip Ozuah. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 380,000. View filing ↗
- Section 08, Deborah Leone. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 370,000. View filing ↗
- Section 08, R. Alan Ezekowitz. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 370,000. View filing ↗
- Section 08, Cynthia M. Patton. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 370,000. View filing ↗
- Section 08, Helene Gayle. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 363,656. View filing ↗
- Section 08, Grace Puma. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 360,000. View filing ↗
- Section 08, Ramona Sequeira. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 280,000. View filing ↗
- Section 08, Rochelle B. Lazarus. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: —. View filing ↗
- Section 02, Lynette Holzbaur 2026-05-06. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynette Holzbaur 2026-05-06. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lynette Holzbaur 2026-05-06. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Philip Ozuah 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ramona Sequeira 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Essner 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, R. Alan Ezekowitz 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Helene Gayle 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Leone 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia M. Patton 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shalini Sharp 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rochelle B. Lazarus 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Juliana Papa Drinane 2026-08-05. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arjona Ferreira Juan Camilo 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arjona Ferreira Juan Camilo 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arjona Ferreira Juan Camilo 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-11. Item 5.07 · say-on-pay result. As reported: 95.12% (votes for as printed: 142,593,022). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-12. Item 5.07 · say-on-pay result. As reported: 78.92% (votes for as printed: 131,520,446). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-06. Item 5.07 · say-on-pay result. As reported: 84.15% (votes for as printed: 149,712,445). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 1,343,441 + equity 2,380,000 + all other 0 = 3,723,441, summed across the director compensation table rows.
- Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
- Baxter International Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Baxter International Inc.'s own proxy. As printed: 29,805,182. View filing ↗
- Iqvia Holdings Inc., Section 10b CEO total. DEF 14A, filed 2026-02-27. CEO total compensation as printed in Iqvia Holdings Inc.'s own proxy. As printed: 28,128,245. View filing ↗
- Biogen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. View filing ↗
- Boston Scientific Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-18. CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. View filing ↗
- Vertex Pharmaceuticals Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Vertex Pharmaceuticals Incorporated's own proxy. As printed: 21,144,261. View filing ↗
- Intuitive Surgical, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in Intuitive Surgical, Inc.'s own proxy. As printed: 20,997,480. View filing ↗
- Jazz Pharmaceutical Plc, Section 10b CEO total. DEF 14A, filed 2026-06-08. CEO total compensation as printed in Jazz Pharmaceutical Plc's own proxy. As printed: 19,151,558. View filing ↗
- Zoetis Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Zoetis Inc.'s own proxy. As printed: 19,046,509. View filing ↗
- Edwards Lifesciences Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-26. CEO total compensation as printed in Edwards Lifesciences Corporation's own proxy. As printed: 17,454,255. View filing ↗
- Hologic, Inc., Section 10b CEO total. DEF 14A, filed 2025-01-16. CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. View filing ↗
- Viatris Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Viatris Inc.'s own proxy. As printed: 15,273,331. View filing ↗
- Elanco Animal Health Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Elanco Animal Health Incorporated's own proxy. As printed: 14,925,756. View filing ↗
- Agilent Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-02-06. CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. View filing ↗
- Regeneron Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. View filing ↗
- Catalent, Inc., Section 10b CEO total. DEF 14A, filed 2023-12-15. CEO total compensation as printed in Catalent, Inc.'s own proxy. As printed: 6,583,672. View filing ↗
- Avantor, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Avantor, Inc.'s own proxy. As printed: 5,895,624. View filing ↗
- Organon & Co. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Organon & Co.'s own proxy. As printed: 5,772,848. View filing ↗
- Section 10a, Viatris Inc. reciprocity. DEF 14A. Viatris Inc. names Organon & Co. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Jazz Pharmaceutical Plc reciprocity. DEF 14A. Jazz Pharmaceutical Plc names Organon & Co. in its own disclosed peer group (read from its most recent proxy). View filing ↗